BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 100 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q2 2016. The put-call ratio across all filers is 0.18 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $164,000 | -78.0% | 34,500 | -90.7% | 0.60% | +51.8% |
| Q1 2020 | $745,000 | +12.2% | 372,700 | +93.6% | 0.40% | +407.7% |
| Q4 2019 | $664,000 | +19.9% | 192,479 | -0.5% | 0.08% | +9.9% |
| Q3 2019 | $554,000 | +77.6% | 193,478 | +134.8% | 0.07% | +222.7% |
| Q2 2019 | $312,000 | -20.4% | 82,400 | +71.0% | 0.02% | +22.2% |
| Q1 2019 | $392,000 | +14.0% | 48,200 | -19.9% | 0.02% | -10.0% |
| Q2 2018 | $344,000 | -33.3% | 60,200 | -66.9% | 0.02% | -58.3% |
| Q2 2016 | $516,000 | -65.6% | 181,800 | -65.7% | 0.05% | -68.4% |
| Q1 2016 | $1,500,000 | +65.9% | 530,100 | +505.1% | 0.15% | +32.2% |
| Q4 2015 | $904,000 | +18.3% | 87,600 | +11.9% | 0.12% | 0.0% |
| Q3 2014 | $764,000 | -46.4% | 78,300 | -30.0% | 0.12% | -45.8% |
| Q2 2014 | $1,425,000 | +154.0% | 111,900 | +110.7% | 0.21% | +143.7% |
| Q1 2014 | $561,000 | – | 53,100 | – | 0.09% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 3,846,154 | $27,230,770 | 26.28% |
| Prosight Management, LP | 2,408,135 | $17,049,596 | 5.40% |
| Kynam Capital Management, LP | 3,133,193 | $22,183,006 | 3.63% |
| Saturn V Capital Management LP | 982,458 | $6,955,803 | 2.91% |
| AlphaCentric Advisors LLC | 649,000 | $4,594,920 | 2.61% |
| TANG CAPITAL MANAGEMENT LLC | 1,800,000 | $12,744,000 | 1.80% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 791,671 | $5,605,031 | 1.70% |
| Eversept Partners, LP | 2,479,103 | $17,552,049 | 1.48% |
| DAFNA Capital Management LLC | 652,000 | $4,616,160 | 1.44% |
| Avoro Capital Advisors LLC | 11,550,000 | $81,774,000 | 1.28% |